Mark Brantly

Mark Brantly

University of Florida

H-index: 65

North America-United States

About Mark Brantly

Mark Brantly, With an exceptional h-index of 65 and a recent h-index of 31 (since 2020), a distinguished researcher at University of Florida, specializes in the field of misfolded proteins, proteostasis, alpha-1 antitrypsin deficiency, rare lung diseases.

His recent articles reflect a diverse array of research interests and contributions to the field:

Alpha-1 Antitrypsin Deficiency in a Young Never Smoker With Novel Null Homozygous Mutation: A Case Report

The Exacerbation of the Inflammatory Response to Nontypeable Haemophilus Influenzae Bacteria by Alpha-Defensins

New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease

Monocyte NLRP3 inflammasome and interleukin-1β activation modulated by alpha-1 antitrypsin therapy in deficient individuals

Sirtuin3 promotes the degradation of hepatic Z alpha-1 antitrypsin through lipophagy

Novel SERPINA1 alleles identified through a large alpha-1 antitrypsin deficiency screening program and review of known variants

Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans

Biomarkers for assessing liver disease

Mark Brantly Information

University

Position

Professor of Medicine

Citations(all)

14632

Citations(since 2020)

3968

Cited By

12290

hIndex(all)

65

hIndex(since 2020)

31

i10Index(all)

158

i10Index(since 2020)

98

Email

University Profile Page

University of Florida

Google Scholar

View Google Scholar Profile

Mark Brantly Skills & Research Interests

misfolded proteins

proteostasis

alpha-1 antitrypsin deficiency

rare lung diseases

Top articles of Mark Brantly

Title

Journal

Author(s)

Publication Date

Alpha-1 Antitrypsin Deficiency in a Young Never Smoker With Novel Null Homozygous Mutation: A Case Report

A Hong

A Hoover

SF Nelson

S Yoon

ML Brantly

...

2024/5

The Exacerbation of the Inflammatory Response to Nontypeable Haemophilus Influenzae Bacteria by Alpha-Defensins

J Lee

Y Lu

N Mohammad

K Han

ML Brantly

2024/5

New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease

Rohit Loomba

Ginger Clark

Jeff Teckman

Veeral Ajmera

Cynthia Behling

...

2024/3/22

Monocyte NLRP3 inflammasome and interleukin-1β activation modulated by alpha-1 antitrypsin therapy in deficient individuals

Thorax BMJ

Debananda Gogoi

Howard Yu

Michelle Casey

Rory Baird

Azeez Yusuf

...

2024/2/28

Sirtuin3 promotes the degradation of hepatic Z alpha-1 antitrypsin through lipophagy

Hepatology Communications

Brittney Poole

Regina Oshins

Zhiguang Huo

Alek Aranyos

Jesse West

...

2024/2/1

Novel SERPINA1 alleles identified through a large alpha-1 antitrypsin deficiency screening program and review of known variants

Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation

Gayle S Wiesemann

Regina A Oshins

Tammy O Flagg

Mark L Brantly

2023

Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans

Biomedicines

Hisae Kuoch

Karina Krotova

Melanie L Graham

Mark L Brantly

George Aslanidi

2023/2/11

Biomarkers for assessing liver disease

2023/6/29

Alpha-defensins inhibit ERK/STAT3 signaling during monocyte-macrophage differentiation and impede macrophage function

Respiratory Research

Jungnam Lee

Naweed Mohammad

Yuanqing Lu

Regina Oshins

Alek Aranyos

...

2023/12/11

Lung inflammation in alpha-1-antitrypsin deficient individuals with normal lung function

Respiratory Research

Nurdan Kokturk

Nazli Khodayari

Jorge Lascano

E Leonard Riley

Mark L Brantly

2023/2/2

OS-120 Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin …

Virginia Clark

Charlton Strange

Pavel Strnad

Antonio Sanchez

Paul Yien Kwo

...

2023/6/1

Correction to: Cigarette smoke exposed airway epithelial cells-derived EVs promote pro-inflammatory macrophage activation in alpha-1 antitrypsin deficiency

Respiratory Research

Nazli Khodayari

Regina Oshins

Borna Mehrad

Jorge E Lascano

Xiao Qiang

...

2023/11/4

Profiling plasma extracellular vesicle-derived microRNAs for noninvasive diagnosis of alpha-1 antitrypsin deficiency associated liver disease

bioRxiv

Regina Oshins

Zhiguang Huo

Brittney Poole

Virginia Clark

Huiping Zhou

...

2023

Association of Neutrophil Elastase-Rich Extracellular Vesicles With Lung and Systemic Inflammation in AATD Subjects

VP Trelles

J Lascano

D Bustamante-Soliz

R Oshins

Z Greenberg

...

2023/5

Treatment for Alpha-1 Antitrypsin Deficiency: Does Augmentation Therapy Work?

Mark Brantly

2023/11/1

Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin …

Journal of hepatology

Virginia Clark

Charlton Strange

Pavel Strnad

Antonio Sanchez

Paul Yien Kwo

...

2023

Recombinant Human Alpha-1 Antitrypsin (AAT) Protein INBRX-101 Demonstrates Potential to Achieve Lung Penetration and Normal Functional Serum AAT Levels in Patients With AAT …

BT Kuhn

A Veale

H Farah

R Mahadeva

CL Chang

...

2023/5

Testing patterns and disparities for alpha-1 antitrypsin deficiency

The American Journal of Medicine

Leonard Riley

Aryaman Sriram

Mark Brantly

Jorge Lascano

2023/10/1

Augmentation Therapy Modulates Systemic Inflammation in Individuals with Alpha-1 Antitrypsin Deficiency and Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation

Jorge E Lascano

Leonard Riley

Nazli Khodayari

Mark L Brantly

2023

Lung microhaemorrhage drives oxidative/inflammatory damage in α1-antitrypsin deficiency

ERJ Open Research

Cesare Saltini

Naweed Mohammad

Yan Xin

Rodolfo Alvarado

Andrew J Ghio

...

2023/5/1

See List of Professors in Mark Brantly University(University of Florida)